Clinical Report: Hoth Applies AI in Development of Candidate for KIT-Driven Cancers

Overview

Hoth Therapeutics is utilizing AI to advance its investigational therapy HT-KIT for KIT-driven cancers, achieving significant preclinical results. The therapy has shown over 80% reduction in KIT mRNA and protein expression, with favorable safety data, and is set to enter phase I clinical evaluation following IND submission.

Background

KIT-driven cancers, such as gastrointestinal stromal tumors (GIST) and systemic mastocytosis (SM), represent significant clinical challenges due to their aggressive nature and limited treatment options. The integration of AI in drug development is becoming increasingly important, as it enhances data analysis and regulatory preparation, potentially accelerating the path to clinical trials. Hoth's approach reflects a broader trend in the biopharmaceutical industry to leverage AI technologies in various stages of drug development.

Data Highlights

Key Findings

• HT-KIT targets rare cancers driven by KIT mutations, including GIST and SM.
• Preclinical studies demonstrated over 80% reduction in KIT mRNA and protein expression.
• Significant tumor-volume reductions were observed in xenograft models within eight days.
• No dose-limiting toxicities were reported in preclinical safety studies.
• AI integration supports regulatory documentation and IND submission preparation.

Clinical Implications

The promising preclinical results of HT-KIT suggest it may offer a new therapeutic option for patients with KIT-driven cancers, addressing a significant unmet medical need. The use of AI in drug development could streamline processes and enhance the efficiency of bringing new therapies to clinical evaluation.

Conclusion

Hoth Therapeutics' application of AI in the development of HT-KIT represents a significant advancement in targeting KIT-driven cancers, with encouraging preclinical results paving the way for future clinical trials.

References

1. Hoth Therapeutics, Hoth Therapeutics Press Release, 2023 -- Hoth Applies AI in Development of Candidate for KIT-Driven Cancers
2. The ASCO Post — AI Tool Shows Early Ability in Pinpointing Cells Driving Aggressive Cancers
3. The ASCO Post — Can Artificial Intelligence Predict Treatment Response and Outcomes in Breast Cancer?
4. The ASCO Post — Machine Learning Approach Accelerates Discovery of Novel CDK9 Inhibitors
5. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines
6. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial | Nature Medicine
7. dana-farber — Dana-Farber Researchers Create Experimental AI-based Oncologist’s Assistant
8. FDA approves avapritinib for advanced systemic mastocytosis
9. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines
10. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial | Nature Medicine